Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil
Authors:
Open Access
- 26 March 2018
- journal article
- research article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 8 (5) , 699-702
Abstract
We herein describe the findings from the trifluridine/tipiracil (TAS-102) Compassionate Use program in Latvia, set up prior to marketing authorization for the management of pretreated patients with metastatic colorectal cancer (mCRC). The efficacy and safety of TAS-102 in patients with refractory mCRC were evaluated in the phase III trial RECOURSE. A previous report confirmed neutropenia and duration of previous treatment for mCRC as prognostic factors in TAS-102 users. The aim of the present study was to analyze possible prognostic factors, such as neutropenia, in TAS-102 responders. A retrospective analysis of 14 patients who received TAS-102 chemotherapy in two institutions in Latvia (Clinic of Oncology of Pauls Stradins Clinical University Hospital and Oncology Centre of Riga East University Hospital) was performed. Grade 3-4 neutropenia was observed in 28% of the patients. In patients with grade 3-4 neutropenia the median progression-free survival (mPFS) was 7 months, whereas in those without neutropenia the mPFS was 5 months [hazard ratio (HR)=0.24, P=0.033]. In 64% of the patients, the duration of previous treatment was >18 months. In patients treated for >18 months from the start of first-line mCRC treatment the mPFS was 7 months, whereas in those treated for ≤18 months from the start of first-line mCRC treatment the mPFS was 5 months (HR=0.15, P=0.029). Therefore, a longer time from mCRC diagnosis until disease progression may be used to select chemotherapy-refractory mCRC patients for TAS-102 treatment. Furthermore, severe neutropenia may be considered as a surrogate marker for predicting TAS-102 treatment outcomes.Keywords
This publication has 8 references indexed in Scilit:
- TAS 102 in refractory metastatic colorectal cancer: UK Expanded Access Programme experience.Journal of Clinical Oncology, 2017
- Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102Clinical Colorectal Cancer, 2017
- DI-064 Evaluation of tas-102 as an expanded access in refractory colorectal cancer2017
- Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy2017
- Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overviewAnnals of Oncology, 2016
- PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancerAnnals of Oncology, 2016
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialThe Lancet Oncology, 2012